The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Managing CNS-involved myeloma: CAR T-cell access and alternative treatment strategies
Sven Neubert, MD, University Hospital Wuerzburg, Wuerzburg, Germany, discusses treatment considerations for patients with multiple myeloma and central nervous system (CNS) involvement who lack access to CAR T-cell therapy. Dr Neubert emphasizes the importance of early referral to specialist centers, ideally before bridging therapy, and discusses alternative approaches including radiotherapy, systemic treatment, and intrathecal therapy, while acknowledging their limited potential for durable responses. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
